Tadehaginoside modulates lipogenesis and glucose consumption in HepG2 cells

Abstract

<div><p>Tadehaginoside (TS) is a phenylpropanoid glycoside found in <i>Tadehagi triquetrum</i>, a medicinal plant with multiple biological activities. This study investigated the effect of TS on lipogenesis and glucose consumption in HepG2 cells. Treatment with TS inhibited lipid accumulation in a dose-dependent manner. This inhibition was closely associated with the downregulation of lipogenic genes such as <i>SREBP-1a</i>, <i>SREBP-2</i> and their downstream targets (<i>FAS</i>, <i>ACC</i>, <i>HMGR</i>) and the upregulation of lipolytic gene <i>PPARα</i> as revealed by real-time quantitative PCR. Further investigation showed that TS significantly stimulated glucose consumption by HepG2 cells and glucose uptake by C2C12 myotubes, which could be partially explained by the upregulation of <i>PPARγ</i>. Collectively, these results clearly indicate that TS is an effective regulator of lipogenesis and glucose consumption, which could be useful in treatment of obesity and diabetes.</p></div